about £25 000. Whereas the cost per life year gained of £8000 for a five yearly interval may be considered acceptable, the marginal costs per life year gained by screening every three years are high in comparison with the costs of many other health care facilities. In addition, we found that increasing the screening frequency will worsen the balance between favourable and adverse health effects (unnecessary treatment of women with false positive results and regressive lesions) of screening.11
Our analysis is based on published data from studies that are now more than 10 years old. Reports of an increasing incidence and mortality, especially in younger women, do not influence our results since our estimates are predominantly determined by the duration ofpreinvasive stages and the sensitivity of the screening test. These factors could also change over time,'2 stressing the need for continuous re-evaluation of the protection afforded by negative smear test results.
Conclusion
The most serious negative effects of cervical cancer are early death and the serious morbidity associated with advanced disease. Therefore, reduction ofthe risk of death from cervical cancer should be the primary criterion in evaluating screening policies. Reduction in incidence of invasive cancer carries an additional benefit since some major therapeutic procedures and their associated morbidity will be avoided, but this should be considered in conjunction with the negative health effects of diagnostic and therapeutic procedures that are induced by screening."
The use of reduction in incidence as a proxy for reduction in mortality is appealing. However, we have shown that protection against invasive cancer underestimates protection against mortality. The two criteria will lead to different recommendations: screening intervals based on mortality are about 50% longer than those based on incidence. This difference is caused by the good survival of women with screen detected invasive cancers.
On the basis of our calculations of the reduction in cervical cancer Omeprazole is thought to act to reduce gastric acid through specific binding to the parietal cell proton pump hydrogen ion potassium ATPase. Selectivity is further strengthened by the drug's basic nature causing it to accumulate in acid spaces, where it is activated. Both cimetidine and ranitidine have been reported to cause gynaecomastia and impotence, though, unlike cimetidine, ranitidine does not bind to androgen receptors. There have been two single case reports of gynaecomastia during treatment with omeprazole.'2 We add further cases and also record cases ofimpotence related to omeprazole. All had been reported within the World Health Organisation's programme for international drug monitoring as cases, and in all cases causality seemed possible.
Case histories
The cases represent the total reported experience of these adverse drug reactions up to December 1991. There were 15 cases of impotence and 15 of gynaecomastia or breast enlargement.
Impotence-All cases of impotence were in men (mean age 52 6 years). They had been taking 20-40 mg omeprazole daily for a mean of four days (cases in which exact dates were recorded only) before onset. Other drugs were not reported in eight cases and not used in three. The treated condition was mostly reflux oesophagitis (12 cases). Full details of patients are given in the table.
Gynaecomastia or breast enlargement-Gynaecomastia occurred in 13 men (mean, age of 56 8 years), and breast enlargement occurred in two women aged 41 and 77. The doses ofomeprazole used were 20 mg daily in most patients, 40 mg daily in two men, 60 mg daily in one man, and either unknown or intermittent in three patients, including one woman. The mean time to onset (kiiown in 12 cases) was 2 9 months. Most of the patients had either gastric or duodenal ulceration, only three having oesophagitis. In three cases the diagnosis was not recorded. One patient had the Zollinger-Ellison syndrome. The table gives details of the patients.
Comment
There have been two single case reports of gynaecomastia in patients' taking omeprazole but none of impotence. Both reports point out that the mechanism -for the gynaecomastia is not apparent from the pharmacology of the drug. The cases we report are further evidence of the adverse reaction and come from eight different countries. Furthermore, they include the hitherto unrecorded adverse effect of impotence. seemed unlikely in 14 of the patients with adequate information to make a judgment.
The relation of cimetidine to gynaecomastia and impotence is explicable pharmacologically, but ranitidine has also been incriminated in a few cases. A pertinent question is therefore whether the treated disease may be implicated. Severe liver disease, in which gynaecomastia and impotence may feature, is associated with a high incidence of peptic ulceration but is unlikely to go unrecognised in so many reports. Increased prolactin concentrations occur in Wermer's syndrome (multiple endocrine neoplasia, type I) as well as peptic ulceration, but in the cases of gynaecomastia and impotence associated with omeprazole reported to date prolactin and other relevant hormone concentrations were normal. Inhibition of cytochrome P-450 as postulated for gynaecomastia and impotence caused by cimetidine is possible also in the case of omeprazole as it too has some properties inhibiting liver cytochrome P-450 enzyme.34
That seven of the patients with impotence and five of those with gynaecomastia either had recovered or were improving at the time of this report is strong evidence that omeprazole was the causative agent. These cases occurred in several countries participating in the WHO collaborative programme, and the information was gained and assessed in different ways. Causality cannot therefore be simply determined from the information available, and our conclusion does not necessarily represent the opinion of the WHO.
We are grateful to the participating countries in the WHO programme for international drug monitoring for help in preparing this manuscript.
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